Relmada Therapeutics, Inc. Common Stock RLMD
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $12.33 (+168.7% upside)
Key Stats
- Today's Range
- $4.57 – $4.72
- 50-Day Range
- $4.35 – $7.12
- 52-Week Range
- $0.55 – $8.00
- Volume
- 1.03 million shs
- Average Volume
- 1.42 million shs
- Market Cap
- $488.55 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Relmada Therapeutics, Inc. Common Stock
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Related Stocks
Compare head-to-head: RLMD vs LLY·RLMD vs JNJ·RLMD vs ABBV·RLMD vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.